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Abstract
Tumor is heterogeneous – a tumor sample usually consists of a set of subclones with
distinct transcriptional profiles and potentially different degrees of aggressiveness and
responses to drugs. Understanding tumor heterogeneity is therefore critical to precise
cancer prognosis and treatment. In this paper, we introduce BayCount, a Bayesian
decomposition method to infer tumor heterogeneity with highly over-dispersed RNA
sequencing count data. Using negative binomial factor analysis, BayCount takes into
account both the between-sample and gene-specific random effects on raw counts of
sequencing reads mapped to each gene. For posterior inference, we develop an effi-
cient compound Poisson based blocked Gibbs sampler. Through extensive simulation
studies and analysis of The Cancer Genome Atlas lung cancer and kidney cancer RNA
sequencing count data, we show that BayCount is able to accurately estimate the
number of subclones, the proportions of these subclones in each tumor sample, and
the gene expression profiles in each subclone. Our method represents the first effort in
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characterizing tumor heterogeneity using RNA sequencing count data that simultane-
ously removes the need of normalizing the counts, achieves statistical robustness, and
obtains biologically/clinically meaningful insights.
KEY WORDS: Cancer genomics, compound Poisson, Markov chain Monte Carlo,
negative binomial, over-dispersion
1 Introduction
Tumor heterogeneity (TH) is a phenomenon that describes distinct molecular profiles of
different cells in one or more tumor samples. TH arises during the formation of a tumor
as a fraction of cells acquire and accumulate different somatic events (e.g., mutations in
different cancer genes), resulting in heterogeneity within the same biological tissue sample
and between different ones, spatially and temporally (Russnes et al., 2011; Ding et al., 2012).
As a result, tumor cell populations are composed of different subclones (subpopulations) of
cells, characterized by distinct genomes, transcriptional profiles (Kim et al., 2015), as well as
other molecular profiles, such as copy number alterations. Understanding TH is critical to
precise cancer prognosis and treatment. Heterogenetic tumors may exhibit different degrees
of aggressiveness and responses to drugs among different samples due to genetic or gene
expression differences. The level of heterogeneity itself can be used as a biomarker to predict
treatment response or prognosis since more heterogeneous tumors are more likely to contain
treatment-resistant subclones (Marusyk et al., 2012). This will ultimately facilitate the
rational design of combination treatments, with each distinct compound targeting a specific
tumor subclone based on its transcriptional profile.
Large-scale sequencing techniques provide valuable information for understanding tumor
complexity and open a door for the desired statistical inference on TH. Previous studies have
focused on reconstructing the subclonal composition by quantifying the structural subclonal
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copy number variations (Carter et al., 2012; Oesper et al., 2013), somatic mutations (Nik-
Zainal et al., 2012; Roth et al., 2014; Xu et al., 2015), or both (Deshwar et al., 2015; Lee
et al., 2016). In this paper, we aim to learn tumor transcriptional heterogeneity using RNA
sequencing (RNA-Seq) data.
In the analysis of gene expression data, matrix decomposition models have been exten-
sively studied in the context of microarray and normalized RNA-Seq data (Venet et al., 2001;
La¨hdesma¨ki et al., 2005; Wang et al., 2006; Abbas et al., 2009; Repsilber et al., 2010; Shen-
Orr et al., 2010; Gong et al., 2011; Hore et al., 2016; Wang et al., 2016). Generally, given
gene expression data matrix X = (xij)G×S, where the (i, j)th element records the expression
value of the ith gene in the jth sample, they decompose X by modeling xij with
∑K
k=1 φikθkj,
where φik encodes the expression level of the ith gene in the kth subclone, θkj represents the
mixing weight of the kth subclone in the jth sample, and K is the number of subclones. The
decomposition can be solved by either optimization algorithms (Venet et al., 2001; Wang
et al., 2016) or statistical inference by assuming a normal distribution on xij. While it is
reasonable to assume normality for microarray gene expression data, it is often inappropriate
to adopt such an assumption for directly modeling RNA-Seq data, which involve nonnegative
integer observations. If a model based on normal distribution is used, one often needs to
first normalize RNA-Seq data before performing any downstream analysis. See Dillies et al.
(2013) for a review on normalization methods. Although normalization often destroys the
nonnegative and discrete nature of the RNA-Seq data, it remains the predominant way for
data preprocessing due to not only the computational convenience in modeling normalized
data, but also the lack of appropriate count data models. Distinct from previously proposed
methods, in this paper, we propose an attractive class of count data models in decomposing
RNA-Seq count matrices.
There are, nevertheless, statistical challenges with RNA-Seq count data. First, the dis-
tributions of the RNA-Seq count data are typically over-dispersed and sparse. Second, the
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scales of the read counts in sequencing data across samples can be enormously different due
to the mechanism of the sequencing experiment such as the variations in technical lane ca-
pacities. The larger the library sizes (i.e., sequencing depth) are, the larger the read counts
tend to be. In addition, the differences in gene lengths or GC-content (Pickrell et al., 2010)
can bias gene differential expression analysis, particularly for lowly expressed genes (Oshlack
and Wakefield, 2009). A number of count data models have been developed for RNA-Seq
data (Lee et al., 2013; Kharchenko et al., 2014; Fan et al., 2016). For example, Lee et al.
(2013) proposed a Poisson factor model on microRNA to reduce the dimension of count
data and identify low-dimensional features, followed by a clustering procedure over tumor
samples. Kharchenko et al. (2014) developed a method using a mixture of negative binomial
and Poisson distributions to model single cell RNA-Seq data for gene differential expression
analysis. None of these methods, however, address the problem of TH.
To this end, we propose BayCount, a Bayesian matrix decomposition model built upon
the negative binomial model (Zhou, 2016), to infer tumor transcriptional heterogeneity using
RNA-Seq count data. BayCount accounts for both the between-sample and gene-specific
random effects and infers the number of latent subclones, the proportions of these subclones
in each sample, and subclonal expression simultaneously.
The remainder of the paper is organized as follows. In Section 2, we introduce BayCount,
a hierarchical Bayesian model for RNA-Seq count data, and develop an efficient compound
Poisson based blocked Gibbs sampler. We investigate the performance of posterior inference
and robustness of the BayCount model through extensive simulation studies in Section 3,
and apply our proposed BayCount model to analyze two real-world RNA-Seq datasets from
The Cancer Genome Atlas (TCGA) (The Cancer Genome Atlas Network et al., 2012) in
Section 4. We conclude the paper in Section 5.
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2 Hierarchical Bayesian Model and Inference
In this section we present the proposed hierarchical model for RNA-Seq count data, develop
the corresponding posterior inference, and discuss how to determine the number of subclones.
2.1 BayCount Model
We assume that S tumor samples are available from the same or different patients. Consider
a G×S count matrix Y = (yij)G×S, where each row represents a gene, each column represents
a tumor sample, and the element yij records the read count of the ith gene from the jth tumor
sample. The Poisson distribution Pois(λ) with mean λ > 0 is commonly used for modeling
count data. Poisson factor analysis (PFA) (Zhou et al., 2012) factorizes the count matrix Y
as yij ∼ Pois
(∑K
k=1 φikθkj
)
, where Φ = (φik)G×K ∈ RG×K+ is the factor loading matrix and
Θ = (θkj)K×S ∈ RK×S+ is the factor score matrix. Here K is an integer indicating the number
of latent factors, and each column of Φ is subject to the constraint that
∑G
i=1 φik = 1 and
φij ≥ 0. However, the restrictive equidispersion property of the Poisson distribution that the
variance and mean are the same limits the application of PFA in modeling sequencing data,
which are often highly over-dispersed. For this reason, one may consider negative binomial
factor analysis (NBFA) of Zhou (2016) that factorizes Y as yij ∼ NB
(∑K
k=1 φikθkj, pj
)
,
where pj ∈ (0, 1). We denote y ∼ NB(r, p) as a negative binomial distribution with shape
parameter r > 0 and success probability p ∈ (0, 1), whose mean and variance are rp/(1− p)
and rp/(1− p)2, respectively, with the variance-to-mean ratio as 1/(1− p).
Denote the jth column of Y as yj = (y1j, y2j, . . . , yGj)
T , the count profile of the jth
tumor sample. To account for both the between-sample and gene-specific random effects
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when modeling RNA-Seq count data, we propose
yij | λ, αi, ζj, pj,Φ,Θ ∼ NB
(
λαi +
K∑
k=1
φikθkjζj, pj
)
, (2.1)
where αi accounts for the gene-specific random effect of the ith gene, λ and pj control the
scales of the gene-specific effect and between-sample effect of the jth sample, respectively,
and
∑K
k=1 φikθkjζj represents the average effect of the K subclones on the expression of the
ith gene in the jth sample.
To see this, recall that the mean of yij based on (2.1) is
E[yij] =
(
λαi +
K∑
k=1
φikθkjζj
)
pj
1− pj . (2.2)
Since pj is sample-specific, the term pj/(1− pj) describes the effect of sample j on read
counts due to technical or biological reasons (e.g., different library sizes, biopsy sites, etc).
We assume the relative expression of the ith gene in the kth subclone is described by φik,
where φik ≥ 0. Since the sample-specific effect has already been captured by pj, for modeling
convenience, we normalize the gene expression so that the expression levels sum to one for
each subclone. Namely,
∑G
i=1 φik = 1 for all k = 1, · · · , K. Furthermore, we assume that
θkj represents the proportion of the kth subclone in the jth sample, where θkj ≥ 0 and∑K
k=1 θkj = 1. We can interpret θkjζj as the population frequencies of the kth subclone in the
jth sample, where parameter ζj controls the scale. Together, the summation
∑K
k=1 φikθkjζj
represents the aggregated expression level of the ith gene across all K subclones for the jth
sample. To further account for the gene-specific random effects that are independent of the
samples and subclones, we introduce an additional term λαi to describe the random effect of
the ith gene on the read counts such as GC-content and gene length. We assume
∑G
i=1 αi = 1
so that αi represents the relative gene-specific random effect of the ith gene with respect to
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all the genes and λ controls the overall scale of the gene-specific random effects.
Following Zhou (2016), the model in (2.1) has an augmented representation as
yij = xij + zij,
xij =
K∑
k=1
xijk,
zij | λ, αi, pj ∼ NB(λαi, pj),
xijk | φk,θj, ζj, pj ∼ NB (φikθkjζj, pj) . (2.3)
From (2.3), the raw count yij of the ith gene in the jth sample can be interpreted as coming
from multiple sources: xijk represents the count of the ith gene contributed by the kth
subclone in the jth sample, where k = 1, . . . , K, while zij is the count contributed by the
gene-specific random effect of the ith gene in the jth sample.
Denote y·j =
∑G
i=1 yij. Since
∑G
i=1 φik = 1 and
∑K
k=1 θkj = 1 by construction, under
(2.3), by the additive property of independent negative binomial random variables with the
same success probability, we have
y·j | λ, αi, ζj, pj,Φ,Θ ∼ NB (λ+ ζj, pj) ,
and, in particular, the mean as E[y·j] = (λ + ζj)pj/(1− pj) and the variance as Var(y·j) =
E[y·j] + E2[y·j]/(λ + ζj). It is clear that pj, the between-sample random effect of the jth
sample, governs the variance-to-mean ratio of y·j, whereas λ + ζj, the sum of the scale λ of
the gene-specific random effects and the scale ζj for the jth sample, controls the quadratic
relationship between Var(y·j) and E[y·j].
We complete the model by setting the following priors that will be shown to be amenable
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to posterior inference:
φk ∼ Dirichlet(η, · · · , η), α ∼ Dirichlet(δ, · · · , δ),
θj | r1, · · · , rK ∼ Dirichlet (r1, · · · , rK) , pj ∼ Beta(a0, b0),
ζj | r1, · · · , rK , cj ∼ Gamma
(
K∑
k=1
rk, c
−1
j
)
, λ ∼ Gamma (u0, v−10 ) ,
where φk = (φ1k, · · · , φGk)T , θj = (θ1j, · · · , θKj)T , α = (α1, · · · , αG)T , Gamma(a, b) denotes
a gamma distribution with mean ab and variance ab2, and Dirichlet(η1, · · · , ηd) denotes a
d-dimensional Dirichlet distribution with parameter vector (η1, · · · , ηd). We further impose
the hyperpriors, expressed as rk | γ0, c0 ∼ Gamma
(
γ0/K, c
−1
0
)
, cj ∼ Gamma
(
e0, f
−1
0
)
,
γ0 ∼ Gamma
(
g0, h
−1
0
)
, and c0 ∼ Gamma
(
e0, f
−1
0
)
to construct a more flexible model.
Shown in Figure 1 is the graphical representation of our BayCount model.
2.2 Gibbs Sampling via Data Augmentation
For the proposed BayCount model, while the conditional posteriors of pj, cj and c0 are
straightforward to derive due to conjugacy, a variety of data augmentation techniques are
used to derive the closed-form Gibbs sampling update equations for all the other model
parameters. Rather than going into the details here, let us first assume that we have already
sampled the latent counts xijk given the observations yij and model parameters, which,
according to Theorem 1 of Zhou (2016), can be realized by sampling from the Dirichlet-
multinomial distribution; given xijk, we show how to derive the Gibbs sampling update
equations for Φ and Θ via data augmentation; and we will describe in the Supplementary
Material a compound Poisson based blocked Gibbs sampler that completely removes the
need of sampling xijk.
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Figure 1: Graphical representation of the BayCount model. The boxes represent replicates.
For example, the box containing rk, xijk and φk, with K in its bottom right corner, indicates
that there are K “copies” of rk, xijk and φk with k = 1, · · · , K. Shaded nodes represent
observations.
Sampling Φ and Θ
We introduce an auxiliary variable `ijk that follows a Chinese restaurant table (CRT) distri-
bution, denoted by `ijk | xijk, φikθkjζj ∼ CRT(xijk, φikθkjζj), with probability mass function
p(`ijk | xijk, φikθkjζj) = Γ(φikθkjζj)
Γ (xijk + φikθkjζj)
|s(xijk, `ijk)| (φikθkjζj)`ijk ,
supported on {0, 1, 2, · · · , xijk}, where s(xijk, `ijk) are Stirling numbers of the first kind
(Johnson et al., 1997). Sampling ` ∼ CRT(x, r) can be realized by taking the summation of
m independent Bernoulli random variables: ` =
∑x
t=1 bt, where bt ∼ Bernoulli (r/(r + t− 1))
independently. Following Zhou and Carin (2012), the joint distribution of `ij and xij de-
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scribed by
`ijk | xijk, φik, θkj, ζj ∼ CRT (xijk, φikθkjζj) ,
xijk | φik, θkj, ζj, pj ∼ NB (φikθkjζj, pj) ,
can be equivalently characterized under the compound Poisson representation
xijk | `ijk, pj ∼ SumLog (`ijk, pj) ,
`ijk | φik, θkj, ζj, pj ∼ Pois (−φikθkjζj log(1− pj)) ,
where x ∼ SumLog (`, p) denotes the sum-logarithmic distribution generated as x = ∑`t=1 ut,
where (ut)
`
t=1 are independent, and identically distributed (i.i.d.) according to the logarith-
mic distribution (Quenouille, 1949) with probability mass function p(u) = −pu/[u log(1−p)],
supported on {1, 2, · · · }.
Under this augmentation, the likelihood of φik, θkj and ζj becomes
L(φik, θkj, ζj) ∝ Pois (`ijk | −φikθkjζj log(1− pj)) ,
where Pois(· | λ) denotes the probability mass function of the Poisson distribution with mean
λ . It follows immediately that the full conditional posterior distributions for φk and θj are
(φk | −) ∼ Dirichlet
(
η +
S∑
j=1
`1jk, · · · , η +
S∑
j=1
`Gjk
)
,
(θj | −) ∼ Dirichlet
(
r1 +
G∑
i=1
`ij1, · · · , rK +
G∑
i=1
`ijK
)
.
Using data augmentation, we can similarly derive the full conditional posterior distribu-
tions for ζj, α, rk and γ0, as described in detail in the Supplementary Material.
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2.3 Determining the Number of Subclones K
We have so far assumed a priori that K is fixed. Determining the number of factors in
factor analysis is, in general, challenging. Zhou (2016) suggested adaptively truncating K
during Gibbs sampling iterations. This adaptive truncation procedure, which is designed
to fit the data well, may tend to choose a large number of factors, some of which may
be highly correlated to each other and hence appear to be redundant. To facilitate the
interpretation of the model output, we seek a model selection procedure that estimates K
in a more conservative manner. To select a moderate K that is large enough to fit the data
reasonably well, but at the same time is small enough for the sake of interpretation, we
generalize the deviance reduction-based approach in Shen and Huang (2008) and calculate
the estimated log-likelihood of the model under different numbers of subclones using post-
burn-in MCMC samples. These samples are obtained by running the compound Poisson
based blocked Gibbs sampler for different K’s. The estimate of K can be identified by
an apparent decrease in the slopes of segments that connect the log-likelihood values of two
consecutive K values. Formally, we denote the log-likelihood function logL(K) as a function
of K, and define the second-order finite difference ∆2 logL(K) of the log-likelihood function
by ∆2 logL(K) := 2 logL(K)− logL(K−1)− logL(K+1), for K = Kmin+1, · · · , Kmax−1,
where Kmin and Kmax are the lower and upper limits of K, respectively. Then an estimate
of K is given by
Kˆ = arg max
K
∆2 logL(K).
3 Simulation Study
In this section, we evaluate the proposed BayCount model through simulation studies. Two
different scenarios are considered.
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• Scenario I: We simulate the data according to the BayCount model itself in (2.1).
In particular, we generate the subclone-specific gene expression data matrix Φ =
(φik)G×Ko ∈ RG×Ko+ by i.i.d. draws of φk ∼ Dirichlet(0.05, · · · , 0.05), the proportion
matrix Θ = (θkj)Ko×S by i.i.d. draws of θj ∼ Dirichlet(0.5, · · · , 0.5), and ζj by i.i.d.
draws of ζj ∼ Gamma(0.5Ko, 1), where i = 1, · · · , G, j = 1, · · · , S, and k = 1, · · · , Ko.
Here G is the number of genes, S is the number of samples, and Ko is the simulated
number of subclones. We set λ = 1, draw α from Dirichlet(0.5, · · · , 0.5), and generate
pj from a uniform distribution such that the variance-to-mean ratio pj/(1− pj) of y·j
ranges from 100 to 106, encouraging the simulated data to be over-dispersed.
• Scenario II: To evaluate the robustness of the BayCount model, under scenario II
we consider simulating the data from a model that is different from the BayCount.
We generate the subclone-specific gene expression data matrix W = (wik)G×Ko ∈
RG×Ko+ by i.i.d. draws of wik ∼ Gamma(0.05, 10), and the proportion matrix Θ =
(θkj)Ko×S by i.i.d. draws of θj ∼ Dirichlet(0.5, · · · , 0.5). We set λ = 1, draw α
from Dirichlet(0.5, · · · , 0.5), and generate pj from a uniform distribution such that the
variance-to-mean ratio pj/(1− pj) of y·j ranges from 100 to 106. The count matrix Y =
(yij)G×S is generated from yij ∼ NB
(
λαi +
∑Ko
k=1wikθkj, pj
)
. Note that in scenario II
the scales of W = (wik)G×Ko are not subject to the constraint
∑G
i=1wik = 1.
We will show that BayCount can accurately recover both the subclone-specific gene
expression patterns and subclonal proportions. The hyperparameters are set to be η =
0.1, a0 = b0 = 0.01, e0 = f0 = 1, g0 = h0 = 1, and u0 = v0 = 100. We consider
K ∈ {2, 3, · · · , 10}. The compound Poisson based blocked Gibbs sampler is implemented
with an initial burn-in of B = 1000 iterations and a total of n = 2000 iterations. The
posterior means and 95% credible intervals for all parameters are computed using the 1000
post-burn-in MCMC samples.
12
3.1 Synthetic data with Ko = 3
We first simulate two datasets with G = 100, S = 20, and Ko = 3 under both scenario I
and scenario II. Under scenario I, the data generation scheme is the same as the BayCount
model. Figure S1 in the Supplementary Material plots ∆2 logL(K) versus K, indicating
Kˆ = 3, which is the same as the simulation truth. The estimated subclone-specific gene
expression matrix Φˆ and subclonal proportions Θˆ are computed as the posterior means of
the post-burn-in MCMC samples. Figure S2 and S3 compare the simulated true Φ and Θ
with the estimated Φˆ and Θˆ, respectively. We can see that both the subclone-specific gene
expression patterns and the subclonal proportions are successfully recovered.
The analysis under scenario II is of greater interest, since the focus is to evaluate the
robustness of BayCount. BayCount yields an estimate of Kˆ = 3, as shown in Figure S4.
We then focus on the posterior inference based on Kˆ = 3. Figure 2 compares the esti-
mated subclonal proportions Θˆ with the simulated true subclonal proportions across sam-
ples, along with the posterior 95% credible intervals. The results show that the estimated
Θˆ approximates the simulated true Θ well. We then report the posterior inference on the
subclone-specific gene expression Φ. Under the BayCount model,
∑G
i=1 φik = 1, hence the
estimated Φˆ by BayCount and the unnormalized gene expression profile matrix W used in
generating the simulated data are not directly comparable. To see whether the gene expres-
sion pattern is recovered, we first normalize W by its column sums as Wˆ = WΛ−1, where
Λ = diag
(∑G
i=1wi1, · · · ,
∑G
i=1wiK
)
, so that wˆik represents the relative expression level of
the ith gene in the kth subclone, and then compare Φˆ with Wˆ . For visualization, the genes
with small standard deviations (less than 0.01) are filtered out due to their indistinguish-
able expressions across different subclones. Figure 3 compares the heatmap of Φˆ, with the
heatmap of the simulated true (normalized) subclone-specific gene expression Wˆ on selected
differentially expressed genes. It is clear that the pattern of subclone-specific gene expression
13
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Figure 2: The estimated subclonal proportions Θˆ across samples j = 1, · · · , 20 for the
synthetic dataset with Ko = 3 under scenario II. Horizontal axis is the index j = 1, · · · , 20
of tumor samples, and vertical axis is the proportion. The green lines represent the estimate
Θˆ, and the red lines represent the simulated true subclonal proportions. The shaded area
represents the posterior 95% credible bands.
estimated by BayCount closely matches the simulation truth.
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Figure 3: Comparison of subclone-specific gene expression patterns for the synthetic dataset
with Ko = 3 under scenario II. Panel (a) is the heatmap of Wˆ , computed by normalizing
the simulated true expression data W by its column sums, and panel (b) is the heatmap of
the estimate Φˆ.
3.2 Synthetic data with Ko = 5
Similarly as in Section 3.1, we simulate two datasets with G = 1000, S = 40, and Ko = 5
under scenarios I and II, respectively. Under scenario I, BayCount yields an estimate of
Kˆ = 5 (Figure S5), and from Figures S6 and S7, both the subclone-specific gene expression
pattern and the subclonal proportions are successfully captured.
Under scenario II, BayCount yields an estimate of Kˆ = 5 (Figure S8). For the subclonal
proportions Θ = (θkj)K×S, Figure 4 shows that the estimated Θˆ successfully recovers the sim-
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ulated true proportions. Notice that the credible bands are narrower than those in Figure 2,
implying relatively smaller variability in estimating subclonal proportions for larger dataset.
Figure S9 presents the autocorrelation plots of the posterior samples of some randomly se-
lected proportions by the compound Poisson based blocked Gibbs sampler, indicating that
the Markov chains mix well.
Figure 5 compares the simulated true (normalized) subclone-specific gene expression Wˆ
with the estimated Θˆ under the inference of BayCount. For this dataset we pre-screen Wˆ with
a threshold 0.008 on the across-subclone standard deviation for all genes for visualization.
The high concordance between the heatmaps of the estimated and true expression patterns of
the differentially expressed genes indicates that the subclone-specific gene expression patterns
have been successfully recovered as well.
In summary, the BayCount model can accurately identify the number of subclones, es-
timate the subclonal proportions in each sample, and recover the subclone-specific gene
expression pattern of the differentially expressed genes.
4 Real-world Data Analysis
We implement and evaluate the proposed BayCount model on the RNA-Seq data from
The Cancer Genome Atlas (TCGA) (The Cancer Genome Atlas Network et al., 2012) to
study tumor heterogeneity (TH) in both lung squamous cell carcinoma (LUSC) and kidney
renal clear cell carcinoma (KIRC). We first run the proposed Gibbs sampler for each fixed
K ∈ {2, 3, · · · , 10}, compute both the posterior mean and 95% credible interval of the log-
likelihood for each fixed K, and estimate K by maximizing ∆2 logL(K) over K. Next, based
on the estimated Kˆ and the posterior samples generated by the proposed Gibbs sampler, we
estimate the proportions of the identified subclones in each tumor sample and the subclone-
specific gene expression, which in turn can be used for a variety of downstream analyses.
16
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Figure 4: Subclonal proportions across samples j = 5, 10, · · · , 35, 40 for the synthetic dataset
with Ko = 5 under scenario II. Horizontal axis is the index of tumor samples, and vertical
axis is the proportion. The green lines represent Θˆ, and red lines represent the simulated
true subclonal proportions. The shaded area represents the posterior 95% credible bands.
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Figure 5: Comparison of subclone-specific gene expression patterns for the synthetic dataset
with Ko = 5 under scenario II. Panel (a) is the heatmap of Wˆ , computed by normalizing
the simulated true expression data W by its column sums, and panel (b) is the heatmap of
the estimated Φˆ.
4.1 TCGA LUSC Data Analysis
We apply the proposed BayCount model to the TCGA RNA-Seq data in lung squamous cell
carcinoma (LUSC), which is a common type of lung cancer that causes nearly one million
deaths worldwide every year. The raw RNA-Seq data for 200 LUSC tumor samples were
processed using the Subread algorithm in the Rsubread package (Liao et al., 2014) to obtain
gene level read counts (Rahman et al., 2015). We select 382 previously reported important
lung cancer genes (Wilkerson et al., 2010) for analysis, such as KRAS, STK11, BRAF, and
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RIT1.
BayCount yields an estimate of five subclones (Figure S10) and their proportions in each
tumor sample are shown in Figure 6. To identify the dominant subclone for each sample, we
compare the estimated Θˆ of the five subclones in each tumor sample, and use them to cluster
the patients. Formally, for each patient j = 1, · · · , S, we compute the dominant subclone
kj = argmaxk=1,··· ,K θˆkj, and then cluster patients according to {j : kj = k}, k = 1, . . . , Kˆ.
That is to say, the patients with the same dominant subclone belong to the same cluster. We
next check if the identified subclones have any clinical utility, e.g., stratification of patients
in terms of overall survival. Figure 7a shows the Kaplan-Meier plots of the overall survival
of the patients in the five clusters identified by their dominant subclones. Indeed, patients
stratified by these five BayCount-identified groups exhibit very distinct survival patterns
(log-rank test p = 0.0194).
Figure 7b shows the expression levels of the top 30 differentially expressed genes (ranked
by the standard deviations of the subclone-specific gene expression levels φik’s in an increasing
order) in these five subclones. Distinct expression patterns are observed among different
subclones. For example, the FTL level is elevated in subclone 1; the expression levels of
several genes encoding keratins (KRT5, KRT6A, etc.) are elevated in subclone 3; and the
COL1A1 and COL1A2 expression levels are elevated in subclone 4. Interestingly, the patients
with these dominant subclones also show the expected survival patterns. The subclone-1
dominated patients have better overall survival. Previous studies show that the expression
of FTL is decreased in lung tumors compared to normal tissues (Kudriavtseva et al., 2009),
and one plausible explanation is that subclone 1 may descend from less malignant cells and
therefore resemble (or consist of) normal cells. Keratins and collagen I (encoded by COL1A1
and COL1A2) are known to play key roles in epithelial-to-mesenchymal transition (EMT),
which subsequently initiates metastasis and promotes tumor progression (DePianto et al.,
2010; Karantza, 2011; Shintani et al., 2008). This agrees with our observation of worse
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Figure 6: Heatmap for the subclonal proportions across LUSC tumor samples j = 1, · · · , 200.
From the heatmap it is clear that subclone 5 occupies relatively larger proportions for a large
number of patients than the other 4 subclones.
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Figure 7: Panel (a) shows the Kaplan-Meier plots of overall survival in the LUSC dataset,
where the patients are stratified by five clusters identified by subclone domination under
the BayCount model. Panel (b) shows the subclone-specific gene expression of the top
differentially expressed genes among five subclones.
prognosis in patients who have either subclone 3 (with elevated Keratin-coding genes) or
subclone 4 (with elevated collagen I coding genes) as their dominant subclone.
4.2 Kidney Cancer (KIRC) Data Analysis
Similarly, we obtain gene level read counts (Liao et al., 2014) for 200 TCGA kidney renal
clear cell carcinoma (KIRC) tumor RNA-seq samples and analyze them with BayCount.
Among a total of 23,368 genes, 966 significantly mutated genes (Network et al., 2013) in
KIRC patients are selected, including VHL, PTEN, MTOR, etc.
BayCount yields an estimate of five subclones in KIRC (Figure S11). Figure 8 shows the
Kaplan-Meier curves of the overall survival of the patients grouped by their dominant sub-
clones (panel a) and the heatmap of the top 30 differentially expressed genes (panel b). Since
we have a large number of genes to begin with, whereas
∑G
i=1 φik = 1 for all k = 1, · · · , K,
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the subclone-specific gene expression estimates Φˆ will be small. For better visualization, we
plot Φˆ in the logarithmic scale. The subclonal proportions across 200 KIRC tumor samples
are shown in Figure S12. As shown in Figure 8, the patients with these dominant subclones
again show distinct survival patterns. One of the poor survival groups (dominated by sub-
clone 5) is characterized by elevated expression of TGFBI, which is known to be associated
with poor prognosis (Zhu et al., 2015) and matches our observation here.
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Figure 8: Panel (a) shows the Kaplan-Meier plots of overall survival in the KIRC dataset,
where the patients are stratified by five clusters identified by subclone domination under the
BayCount model. Panel (b) shows the subclone-specific gene expression (in the logarithmic
scale) of the top differentially expressed genes among the five inferred subclones.
One distinction of our method from conventional subgroup analysis methods is that we
focus on characterizing the underlying subclones (i.e., biologically meaningful subpopula-
tions), by not only their individual molecular profiles but also their proportions. Instead of
grouping the patients by their dominant subclones, we examine the proportion itself in terms
of clinical utility. Interestingly, as shown in Figure 9a, the proportion of subclone 2 increases
with tumor stage: i.e., as subclone 2 expands and eventually outgrows other subclones,
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the tumor becomes more aggressive. In contrast, the proportion of subclone 3 decreases
with tumor stage (Figure 9b). Subclone 3 might be characterized by the less malignant (or
normal-like) cells and takes more proportion in the beginning of the tumor life cycle. As tu-
mor progresses to more advanced stages, subclone 3 could be suppressed by more aggressive
subclones (e.g., subclone 2) and takes a decreasing proportion. Unsurprisingly, the survival
patterns agree with our speculations about subclones 2 and 3, with the patients dominated
by subclone 2 (the more aggressive subclone) and subcolone 3 (the less aggressive subclone)
showing the worst and best survivals, respectively.
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Figure 9: Panel (a): the proportions of subclone 2 in each tumor sample versus their patho-
logic stages (p-value = 0.00173). Panel (b): the proportions of subclone 3 in each tumor
sample versus their pathologic stages (p-value = 0.00299).
More excitingly, we find that the proportions of these two subclones can complement
clinical variables in further stratifying patients. For patients at early stage where the event
rate is low and clinical information is relatively limited, the proportions of subclones 2 and 3
serve as a potent factor in further stratifying patients (Figure S13) when dichotomizing at a
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natural cutoff. Combining our observations above, subclone proportions may provide addi-
tional insights into the progression course of tumors, assistance in biological interpretation,
and potentially more accurate clinical prognosis.
5 Conclusion
The emerging high-throughput sequencing technology provides us with massive information
for understanding tumors’ complex microenvironment and allows us to develop novel statisti-
cal models for inferring tumor heterogeneity. Instead of normalizing RNA-Seq data that may
bias downstream analysis, we propose BayCount to directly analyze the raw RNA-Seq count
data. Overcoming the natural challenges of analyzing raw RNA-seq count data, BayCount
is able to factorize them while adjusting for both the between-sample and gene-specific ran-
dom effects. Simulation studies show that BayCount can accurately recover the subclonal
inference used to generate the simulated data. We apply BayCount to the TCGA LUSC and
KIRC datasets, followed by correlating the subclonal inferences with their clinical utilities
for comparison. In particular, by grouping patients according to their dominant subclones,
we observe distinct and biologically sensible overall survival patterns for both LUSC and
KIRC patients. Moreover, the proportions of the subclones may complement clinical vari-
ables in further stratifying patients. In addition to prognosis value, tumor heterogeneity may
be used as a biomarker to predict treatment response. For example, tumor samples with
large proportions of cells bearing higher expressions on clinically actionable genes should be
treated differently from those that have no or a small proportion of such cells. In addition,
metastatic or recurrent tumors may possess very different compositions of subclones and
should be treated differently.
BayCount provides a general framework for inference on latent structures arising natu-
rally in many other biomedical applications involving count data. For example, analyzing
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single-cell data is a potential further application of BayCount due to their sparsity and over-
dispersion nature. Macosko et al. (2015) describe Drop-Seq, a technology for profiling more
than 40,000 single cells at one time. The unique characteristic of dropped-out events (Fan
et al., 2016) in single cell sequencing limits the applicability of normalization methods in bulk
RNA-Seq data. Also, such huge amount number of single-cells and high levels of sparsity
pose difficulties for dimensionality reduction methods such as principal component analy-
sis. Inferring distinct cell populations in single-cell RNA count data will be an interesting
extension of BayCount.
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